Renal osteodystrophy: Its management in patients on maintenance dialysis;Ostéodystrophie rénale (3); son traitement chez le dialysé

Nephrologie

Volumn 21, Issue 8, 2000, Pages 413-424

  Ghitu, S ^a   Oprisiu, R ^a   Benamar, L ^a   Said, S ^a   Albu, A T ^a   Arsenescu, I ^a   El Esper, N ^a   Moriniere Ph ^a   Fournier, A ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Aluminum (Al); Calcium carbonate (CaCO3); Hyperparathyroidism; Maintenance dialysis; Osteomalacia (OM); Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; ALUMINUM; ALUMINUM HYDROXIDE; AMG 703; CALCIDIA; CALCITRIOL; CALCIUM CARBONATE; CALCIUM CHANNEL STIMULATING AGENT; CINACALCET; COLESTYRAMINE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FALECALCITRIOL; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PARICALCITOL; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ALGORITHM; BONE BIOPSY; CALCIUM BALANCE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; INTOXICATION; KIDNEY FAILURE; OSTEITIS FIBROSA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BALANCE; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

ALUMINUM; CALCIUM CARBONATE; CHELATING AGENTS; DEFEROXAMINE; HUMANS; HYPERPARATHYROIDISM; OSTEOMALACIA; PARATHYROIDECTOMY; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 16744366348     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. The natural course of dialysis osteomalacia
2. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD
3. Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting Al(OH)3 intake: Emergence of an idiopathic adynamic bone disease not related to aluminium
4. Risk of adynamic bone disease in dalyzed patients
5. The spectrum of bone disease in end-stage renal failure: An evolving disorder
6. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH
7. Consensus conference on diagnosis and treatment of aluminium overload in end-stage renal failure patients
8. Ostéopathie adynamique: Quelle signification clinique
9. Aluminium: Much ado about something
10. Adynamic bone disease in patients with uremia
11. Low dose (56 mg/kg) déferoxamine treatment in acutely intoxicated haemodialysis patients using two drug administration schedules
12. The clinical significance of adynamic bone disease in uremia
13. Prevention and medical treatment of hyperparathyroidism secondary to renal failure in the adult
14. Lack of histological evidences of vitamin D abnormality in the bones of anephric patients
15. Importance of vitamin D repletion in uraemia
16. Osteomalacia in patients with chronic renal failure before dialysis or transplantation
17. Native vitamin D relative deficiency as a risk factor of renal osteodystrophy independent of calcitriol?
18. Comparison of 1-alphahydroxycholecalciferol and 25 hydroxycholecalciferol in the treatment of renal osteodystrophy: Greater effect of 25 hydrocholecalciferol on bone mineralization
19. 24,25(OH)2 vitamin D supplementation corrects hyperparathyroidism and improve skeletal abnormalities in X linked hypophosphatemic ricketts
20. Liver granulomatosis: A non exceptional cause of hypercalcemia with relative hypoparathyroidism in dialysis patients
21. Control of hyperphosphatemia in dialyzed patients
22. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. Association of bone disease with potentially etiologic factors; II. Factors affecting serum immunoreactive parathyroid hormone
23. Optimum dialysate calcium concentration during maintenance hemodialysis
24. Use of alkaline calcium salts as phosphate binder in uremic patients
25. Estimation of mass transfer through hemodialysis: Theoretical approach and clinical application
26. Aplastic osteodystrophy without aluminium: The role of suppressed parathyroid function
27. Histological radiological and biochemical features of the adynamic bone lesion in CAPD patients
28. Comparison of 1α OH vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis
29. 1α OH vitamin D3 derivatives in the treatment of renal bone disease: Justification and optimal modalities of administration
30. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients
31. Calcitriol in the management of renal osteodystrophy
32. Suppression of parathyroid hormone by calcitriol therapy in hemodialysis patients. A metaanalysis
33. Intermittent versus continuous administration of 1,25(OH)2 vitamin D3 in experimental renal hyperparathyroidism
34. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial
35. Equal intestinal calcium absorption and greater PTH suppression with oral versus i.v. calcitriol bolus in children with secondary hyperparathyroidism
36. Daily calcitriol but not pulse therapy improves growth in experimental uremia
37. Diminished linear growth during intermittent calcitriol in children undergoing CCPD
38. Soft tissue calcification in uremia
39. Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis lack of influence of calcium carbonate
40. Vascular calcification in long term haemodialysis patients in a single unit: A retrospective analysis
41. Electron beans computed tomography in the evaluation of cardiac calcifications in chronic dialysis patient
42. Adynamic bone disease and osteoporosis in uremic patients
43. Soft tissue calcification in pediatric patient with end stage renal disease
44. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population
45. Hypokinetic azotemic osteodystrophy
46. Aplastic osteodystrophy: Follow up after 5 years
47. Very high incidence and relatively mild clinical symptoms of dialysis population with hypoparathyroidism
48. Incidence and clinical characteristics of hypoprathyroidism in dialysis patients
49. Parathyroid hormone deficiency is an indicator of poor nutritional state and prognosis in dialysis patients
50. Association of serum phosphorus and calcium phosphorus product with mortality risk in chronic hemodialysis patients. A national study
51. Renagel®, a non absorbed calcium and aluminum free phosphate binder, lowers serum phosphorus and parathyroid hormone
52. Long term effects of sevelamer hydrochloride on the calcium phosphoate product and lipid profile on haemodialysis patients
53. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uremic patients
54. De Broe
55. Assessment of combined 24,25(OH)2D3 and 1(OH)D3 therapy for uremic bone disease. Report of the collaborative israeli multicenter trial
56. Effective suppression of parathyroid hormone by 1α hydroxyvitamin D2 in hemodialysis patients with moderates to severe secondary hyperparathyroidism
57. 19-Nor-1α25-Dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
58. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
59. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism
60. 22-oxacalcitriol suppresses secondary hyperparthyroidism without inducind low bone turnover in dogs with renal failure
61. Calcium receptor and calcimimetics
62. Short term inhibition of PTH secretion by calcium-receptor antagonist in patient with primary hyperparatyroidism
63. A calcimimetic agent acutely suppresses PTH levels in patients with chronic renal failure
64. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism
65. NPS R-568 suppresses parathyroid celle proliferation in rats with renal insufficiency